ArticleScientific reports2025
Plant derived extract loaded nanostructured lipid carriers with enhanced oral delivery for the treatment of acute inflammation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid matrix composition-tuned nanoparticles for enhanced topical retinol delivery and anti-photoaging efficacy.International journal of pharmaceutics: X · 2026Article
- Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Xanthorrhizol and curcumin are bioactive compounds derived from plants, including Curcuma xanthorrhiza, a member of the ginger family. However, their limited solubility leads to low oral bioavailability and poses significant constraints for industrial applications. Therefore, we developed nanostructured lipid carriers (NLCs) loaded with standardized ethanolic Curcuma xanthorrhiza extract (CXE). The CXE-NLCs were optimized by varying the initial concentration of CXE, resulting in homogeneous particles with a size of 130.0 ± 1.0 nm and a high encapsulation efficiency of approximately 83%. CXE-NLCs exhibited enhanced biostability under simulated gastrointestinal conditions, and in vitro release studies demonstrated the sustained release of CXE. Additionally, CXE-NLCs demonstrated significantly improved permeability across the Caco-2/HT-29 cell monolayer (Papp = 4.2 × 10− 5 cm/s), which is favorable for the oral delivery of bioactive compounds. In vivo studies confirmed that CXE-NLCs inhibited carrageenan-induced inflammation in the paw, prostaglandins E1 and E2, as well as the eicosanoid and MAPK pathways in a dose-dependent manner. This study highlights the enhanced oral delivery and bioactivity of synthesized CXE-NLCs containing both xanthorrhizol and curcumin in the treatment of acute inflammation. This indicates a useful application and suggests their potential as a nano delivery system for nutraceuticals and pharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.